CBD for Individuals at Risk for Alzheimer's Disease

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT05822362
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Mild Cognitive Impairment

Eligibility Criteria

Sex
ALL
Age
55 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Cannabidiol — DRUG
    The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.
  • Placebo — OTHER
    Placebo arm.

Study Details

This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.

Key Dates

Start date
Jan 19, 2024
Status verified
Sep 2024
Primary completion
Apr 30, 2028
Completion
Apr 30, 2029

Study Design

Enrollment
236 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Full Spectrum Cannabidiol
    200mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
  • Active Comparator: Broad Spectrum Cannabidiol
    200mg/day of broad-spectrum cannabidiol, containing 0.0% THC.
  • Placebo Comparator: Hemp Seed Oil
    200mg/day of hemp seed oil with no cannabinoids present.

Primary Outcome Measure

Neurocognitive Function [ Time Frame: Week 0 to Week 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado - Anschutz Medical CampusAuroraColorado80045
Raeghan Mueller, PhD
[email protected]
Mariah N Brown, MPH
[email protected]

Find similar trials in Aurora, CO

By research site
University of Colorado - Anschutz Medical Campus· Aurora, CO

Related Studies